Hosted on MSN3d
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...
pharmaphorum2y
FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag
Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...
FierceBiotech5d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
pharmaphorum1y
Could Daiichi Sankyo have another ADC winner in cancer?
This morning, the Japanese drugmaker reported updated clinical results from two clinical trials of its HER3-targeted ADC patritumab deruxtecan in metastatic breast cancer and non-small cell lung ...
News Medical3mon
HER3: Emerging as a Key Epidermal Growth Factor Receptor (EGFR) in cancer immunotherapy
One such ADC is Patritumab Deruxtecan. Promising clinical activity is also seen when bispecific antibodies, like zenocutuzumab, target HER3 and HER2. Pharmaceutical companies actively pursue ...
Business Wire5d
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or ...
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by ...
Benzinga.com5d
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd DSNKY and being jointly developed by ...
Nasdaq5d
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...